Clinical Trial

A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis

Terminated Phase 2
View on ClinicalTrials.gov →
Why the trial stopped
Due to the company's strategic adjustment in product portfolio, this study has been voluntarily terminated.
Summary
This is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study, all subjects need to use TQH2929 injection/placebo. The aim was to demonstrate the efficacy and safety of TQH2929 injection in patients with acute exacerbations of generalized pustular psoriasis, with a total of 36 subjects.
Protocol Amendment History 4 changes
critical Trial terminated 2026-08-04
critical Trial terminated: Due to the company's strategic adjustment in product portfolio, this study has been voluntarily terminated. 2026-08-04
notable Primary completion moved earlier: 2026-12 -> 2026-07-30 2026-08-04
minor Completion moved earlier: 2027-07 -> 2026-07-30 2026-08-04
Trial Details
NCT Number NCT07314060
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions Generalized Pustular Psoriasis
Enrollment 36 participants
Start Date 2026-03-19
Primary Completion 2026-07-30 (estimated)
Study Completion 2026-07-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-03